April 11 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* RESULTS FROM XVIVO’S CLINICAL TRIAL NIHP2019 FOR HEART
PRESERVATION PRESENTED AT ISHLT IN PRAGUE
* PRIMARY ENDPOINT, REPRESENTING SEVERE COMPLICATIONS AFTER
HEART
TRANSPLANTATION, WAS REGISTERED IN 18.8% OF SUBJECTS WHO
RECEIVED A DONOR HEART PRESERVED WITH XVIVO HEART ASSIST
TRANSPORT
* 30.1% OF SUBJECTS IN CONTROL GROUP WHO RECEIVED A DONOR
HEART
TRANSPORTED ON ICE
Source text for Eikon: ID:nMFN55cnTM
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))